HUNTINGDON VALLEY, Pa.--(BUSINESS WIRE)--Immunicon Corporation (NASDAQ-GM:IMMC) announced today that the Company entered into two separate agreements with MolMed S.p.A. an Italian pharmaceutical company. The Research Agreement funds development work to develop a biomarker for tumor endothelial cells. Leon Terstappen, Chief Scientific Officer of Immunicon said, “This is a challenging and interesting project.
